Literature DB >> 23383143

APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway.

Guihua Wang1, Feng Wang, Weifeng Ding, Jingchun Wang, Rongrong Jing, Haiquan Li, Xudong Wang, Yueguo Wang, Shaoqing Ju, Huimin Wang.   

Abstract

A proliferation-inducing ligand (APRIL) is highly expressed in colorectal cancer (CRC) tissues and cell lines. However, the biological functions and precise signals elicited by APRIL in CRC have not been fully understood. Here, we used small interfering RNA to selectively deplete APRIL and to determine its tumorigenic effects in a CRC cell line SW480 both in vitro and in vivo. Knockdown of APRIL in SW480 cells was associated with modulation of cell proliferation as well as reduction of cell migration and invasion in vitro. Moreover APRIL-knockdown SW480 cells displayed markedly inhibited tumor growth and decreased metastasis to the liver in immunodeficient mice upon subcutaneous injection. Importantly, we observed that downregulation of APRIL in SW480 cells resulted in greatly decreased activity of phosphoinositide 3-kinase (PI3K)/Akt pathway. In addition, we observed that recombinant human APRIL mediated activation of the PI3K/Akt pathway in CRC cells resulting in induced expression of important cell cycle proteins and matrix metalloproteinases in a PI3K/Akt dependent manner. This was concurrent with marked cell growth viability as well as increased cell migration and invasion. Together, these compelling data suggest that APRIL-induced tumorigenesis and metastasis of CRC cells may be accomplished through activation of the PI3K/Akt pathway. These findings may lead to a better understanding of the biological effects of APRIL and may provide clues for identifying novel therapeutic and preventive molecular markers for CRC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23383143      PMCID: PMC3558491          DOI: 10.1371/journal.pone.0055298

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  34 in total

1.  Reduced APRIL expression induces cellular senescence via a HSPG-dependent pathway.

Authors:  Weifeng Ding; Shaoqing Ju; Shengyang Jiang; Li Zhu; Yueguo Wang; Huimin Wang
Journal:  Pathol Oncol Res       Date:  2009-05-26       Impact factor: 3.201

Review 2.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

3.  APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status.

Authors:  John Quinn; Janet Glassford; Laura Percy; Philippa Munson; Teresa Marafioti; Manuel Rodriguez-Justo; Kwee Yong
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

4.  mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.

Authors:  Pat Gulhati; Kanika A Bowen; Jianyu Liu; Payton D Stevens; Piotr G Rychahou; Min Chen; Eun Y Lee; Heidi L Weiss; Kathleen L O'Connor; Tianyan Gao; B Mark Evers
Journal:  Cancer Res       Date:  2011-03-23       Impact factor: 12.701

5.  APRIL knockdown suppresses migration and invasion of human colon carcinoma cells.

Authors:  Weifeng Ding; Jinchun Wang; Baolan Sun; Shaoqing Ju; Hongxiang Yuan; Xing Wang; Yueguo Wang; Huimin Wang
Journal:  Clin Biochem       Date:  2009-06-30       Impact factor: 3.281

6.  Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: its direct inhibition by quercetin.

Authors:  Mun Kyung Hwang; Nu Ry Song; Nam Joo Kang; Ki Won Lee; Hyong Joo Lee
Journal:  Int J Biochem Cell Biol       Date:  2009-01-29       Impact factor: 5.085

7.  Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.

Authors:  Hui-Hua Zhang; Francesca Walker; Sara Kiflemariam; Robert H Whitehead; David Williams; Wayne A Phillips; Thomas Mikeska; Alexander Dobrovic; Antony W Burgess
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

8.  A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.

Authors:  Mamta Gupta; Stacey R Dillon; Steven C Ziesmer; Andrew L Feldman; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Blood       Date:  2009-03-25       Impact factor: 22.113

9.  Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.

Authors:  Robert T Woodland; Casey J Fox; Madelyn R Schmidt; Peter S Hammerman; Joseph T Opferman; Stanley J Korsmeyer; David M Hilbert; Craig B Thompson
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

10.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Authors:  Elodie Belnoue; Maria Pihlgren; Tracy L McGaha; Chantal Tougne; Anne-Françoise Rochat; Claudia Bossen; Pascal Schneider; Bertrand Huard; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

View more
  20 in total

1.  Tumor necrosis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryngeal squamous cell carcinoma.

Authors:  Ru Wang; Yichao Guo; Hongzhi Ma; Lin Feng; Qi Wang; Xiaohong Chen; Meng Lian; Haizhou Wang; Jugao Fang
Journal:  Tumour Biol       Date:  2015-09-23

2.  Involvement of APRIL in Helicobacter pylori-related gastric cancer.

Authors:  Qun Zhang; Ying Ni; Xiaofei Zhi; Jiwei Wang; Zheng Li; Jie Tang; Linjun Wang; Weizhi Wang; Zekuan Xu
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-18       Impact factor: 4.553

3.  Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.

Authors:  İlay Berke Menteşe; Zeynep Arzu Yegin; Sanem Gökçen; Zübeyde Nur Özkurt; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-10       Impact factor: 0.900

4.  miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.

Authors:  Lin Chen; Haitao Guan; Chunyan Gu; Yali Cao; Jianguo Shao; Feng Wang
Journal:  Tumour Biol       Date:  2015-09-18

5.  Amelioration of colorectal cancer using negative lipidoid nanoparticles to encapsulate siRNA against APRIL by enema delivery mode.

Authors:  Weifeng Ding; Guihua Wang; Keke Shao; Feng Wang; Hua Huang; Shaoqing Ju; Hui Cong; Huimin Wang
Journal:  Pathol Oncol Res       Date:  2014-04-26       Impact factor: 3.201

6.  APRIL depletion induces cell cycle arrest and apoptosis through blocking TGF-β1/ERK signaling pathway in human colorectal cancer cells.

Authors:  Feng Wang; Lin Chen; Hongbin Ni; Guihua Wang; Weifeng Ding; Hui Cong; Shaoqing Ju; Shumei Yang; Huimin Wang
Journal:  Mol Cell Biochem       Date:  2013-07-20       Impact factor: 3.396

7.  Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer.

Authors:  Maoying Fu; Weifei Fan; Xiaolin Pu; Huihui Ni; Wei Zhang; Feng Chang; Li Gong; Lin Xiong; Jun Wang; Xuefeng Gu
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

8.  Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer.

Authors:  K Malinowsky; U Nitsche; K-P Janssen; F G Bader; C Späth; E Drecoll; G Keller; H Höfler; J Slotta-Huspenina; K-F Becker
Journal:  Br J Cancer       Date:  2014-03-11       Impact factor: 7.640

9.  Reduced CTGF expression promotes cell growth, migration, and invasion in nasopharyngeal carcinoma.

Authors:  Yan Zhen; Yanfen Ye; Xiaoli Yu; Chunping Mai; Ying Zhou; Yan Chen; Huiling Yang; Xiaoming Lyu; Ye Song; Qiangyun Wu; Qiaofen Fu; Mengyang Zhao; Shengni Hua; Hao Wang; Zhen Liu; Yajie Zhang; Weiyi Fang
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

10.  RTK/ERK pathway under natural selection associated with prostate cancer.

Authors:  Yang Chen; Xianxiang Xin; Jie Li; Jianfeng Xu; Xiaoxiang Yu; Tianyu Li; Zengnan Mo; Yanling Hu
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.